SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AKYA, CKPT, QTRX on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – BRDG, AKYA, CKPT, QTRX
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Piper Sandler from $2.40 to $1.65. They now have a "neutral" rating on the stock.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities